- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05798455
Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma
March 23, 2023 updated by: Dr. Saeid Safiri, Tabriz University of Medical Sciences
Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma: An Open-label Single-arm Phase 1b/2 Trial
This study investigates the safety and efficacy of sodium pentaborate pentahydrate in patients with advanced renal cell carcinoma.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
There is an increasing trend in the burden of renal cell carcinoma (RCC) globally.
Although different therapies like tyrosine kinase inhibitors, ablative therapy, surgery, and immunotherapy have been suggested for RCC, they are not cost-effective.
The present study will be conducted as an open-label, phase Ib/II study consisting of a dose-escalation stage followed by a cohort expansion stage.
The trial will be conducted in the medical centers affiliated to the Tabriz University of Medical Sciences.
Patients 18 years or older presenting with histologically confirmed RCC with a clear-cell component, that progressed to the advanced or metastatic stage will be recruited.
The dose-escalation stage will determine the schedule and maximum tolerated dose (MTD) and/or recommended Expansion Stage dose of sodium pentaborate pentahydrate.
One oral sodium pentaborate pentahydrate capsule once daily will be considered for evaluation in 21-day treatment cycles: 500 mg, 1000 mg, and 1500 mg.
Subjects will accrue in escalation cohorts of 3-6 subjects using a "3 plus 3" design and dosing will begin at the 500 mg dose level of sodium pentaborate pentahydrate.
During this stage, the decision to open a new cohort will be made when all subjects have been followed for at least 21 days following the first dose of sodium pentaborate pentahydrate(defined as the dose-limiting toxicity (DLT) Evaluation Period).
In the dose-expansion stage, we will further assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of NaB in RCC using the recommended dose and schedule as determined in the dose-escalation stage.
The primary objectives for the dose-escalation stage and dose-expansion stage will be to determine the maximum tolerated dose (MTD) and/or recommended dose and schedule for the subsequent expansion stage and to evaluate the preliminary efficacy of the sodium pentaborate pentahydrate by estimating the objective response rate, respectively.
The investigator will assess each subject continuously to evaluate for potential new or worsening adverse events.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Saeid Safiri, PhD
- Phone Number: +984133342178
- Email: saeidsafiri@gmail.com
Study Locations
-
-
East Azarbayejan
-
Tabriz, East Azarbayejan, Iran, Islamic Republic of, 5166614766
- Imam Reza hospital and clinic of Salamat
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years or older.
- Histological confirmation of RCC with clear cell histology, including participants who may also have sarcomatoid features.
- Advanced (not amenable to curative surgery or radiation) or metastatic disease (American Joint Committee on Cancer [AJCC] stage IV)
- No prior systemic therapy for RCC with the following exception: one prior adjuvant or neoadjuvant therapy for fully resectable RCC if such therapy did not contain an agent targeting vascular endothelial growth factor (VEGF) or VEGF receptors and if at least 6 months after The last dose of adjuvant or neoadjuvant treatment has occurred.
- Karnofsky status score (KPS) 70%
- Measurable disease according to RECIST v1.1 according to the researcher
- Participants with favorable, moderate, and poor risk categories will be eligible for the study.
- Participants had to be stratified according to the International Metastatic RCC Database Consortium (IMDC) criteria according to favorable versus moderate versus poor risk status.
- Adequate hematologic and organ function, based on meeting all laboratory criteria within 14 days prior to the first dose of study treatment
- Patients who are willing and able to provide informed consent/written consent for the trial.
- Sexually active fertile patients and their partners must agree to use highly effective methods of contraception that alone or in combination with consistent and correct use during the study and for 5 months after the last dose of study treatment result in a lower failure rate. from 1% per year. An additional method of contraception, such as a barrier method (such as a condom), is recommended.
- A negative pregnancy test (urine or serum beta-human chorionic gonadotropin [β-hCG]) in screening sexually active women of childbearing potential.
Exclusion Criteria:
- Women who are pregnant, lactating, or planning to become pregnant within 3 months after the last dose of study drug and men who plan to father a child while enrolled in this study or within 5 months after the last dose of study drug.
- Any active central nervous system (CNS) metastases. Participants with treated and stable CNS metastases for at least one month were eligible.
- Any tumor that invades the superior vena cava (SVC), other major blood vessels, or the gastrointestinal tract. Any evidence of intratracheal or intrabronchial tumor
- Prior systemic therapy with VEGF, MET, AXL, KIT, or RET targeted therapy (including, but not limited to, sunitinib, pazopanib, axitinib, tivozanib, sorafenib, lenvatinib, bevacizumab, and cabozantinib)
- Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-CTLA-4 antibody, or any other antibody or drug that specifically co-stimulates T cells or Targets checkpoint routes.
- History of autoimmune disease requiring systemic therapy (eg, using disease-modifying agents, corticosteroids, or immunosuppressive drugs) within the past 2 years.
- Diagnosis of immunodeficiency or receipt of systemic steroid or any other form of immunosuppressive therapy within two weeks prior to the first dose of trial therapy.
- Administration of a live, attenuated vaccine within 30 days before the first dose of study treatment.
- The patient has an uncontrolled or significant intercurrent disease
- Hematuria, hematemesis, or hemoptysis of more than 0.5 teaspoons (2.5 mL) of clinically significant red blood, or other histories of significant bleeding (eg, pulmonary hemorrhage) in the 12 weeks before the first dose.
- Cavity lung lesions or known manifestations of endobronchial disease.
- The lesion invades a major blood vessel including, but not limited to, the inferior vena cava, pulmonary artery, or aorta.
- Known psychiatric or substance abuse disorders that interfere with compliance with trial requirements.
- History or current evidence of any condition, treatment, or laboratory abnormality that may confound the results of the trial, interfere with the patient's participation throughout the trial, or in the opinion of the treating investigator is not in the patient's best interest for participation.
- The participant is currently participating in a study of another investigational agent and has received study treatment or used an investigational device within 4 weeks prior to the first dose of treatment.
- Allergy or previous hypersensitivity to the components of the studied therapeutic formulation has been identified. Patients with a history of infusion-related reactions to prior therapy may be eligible with sponsor approval if the reaction is considered mild and manageable with appropriate supportive care (eg, use of prodrugs per standard of care).
- Individuals with evidence of active malignancy other than RCC (except for curable early-stage cancer such as resected skin cancers and/or completely resected prostate cancer).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention arm
Capsules containing sodium pentaborate pentahydrate 500, 1000 and 1500 mg
|
Capsules containing sodium pentaborate pentahydrate 500, 1000 and 1500 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (MTD) and/or recommended dose
Time Frame: Day 21
|
Determination of maximum tolerated dose (MTD) and/or recommended dose using Response Evaluation Criteria in Solid Tumors version 1.1
|
Day 21
|
Objective response rate
Time Frame: Day 21
|
Objective response rate using Response Evaluation Criteria in Solid Tumors version 1.1
|
Day 21
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response
Time Frame: Days 0, 1, and 21
|
Duration of response using Response Evaluation Criteria in Solid Tumors version 1.1
|
Days 0, 1, and 21
|
Progression free survival
Time Frame: Days 0, 1, and 21
|
Progression free survival using Response Evaluation Criteria in Solid Tumors version 1.1
|
Days 0, 1, and 21
|
Disease control rate
Time Frame: Days 0, 1, and 21
|
Disease control rate using Response Evaluation Criteria in Solid Tumors version 1.1
|
Days 0, 1, and 21
|
Overall survival
Time Frame: Days 0, 1, and 21
|
Overall survival using Response Evaluation Criteria in Solid Tumors version 1.1
|
Days 0, 1, and 21
|
Adverse events
Time Frame: Days 0, 1, and 21
|
Registration of adverse events in questionnaires using Response Evaluation Criteria in Solid Tumors version 1.1
|
Days 0, 1, and 21
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Saeid Safiri, PhD, Tabriz University of Medical Sciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 22, 2023
Primary Completion (Anticipated)
May 22, 2025
Study Completion (Anticipated)
May 22, 2026
Study Registration Dates
First Submitted
March 11, 2023
First Submitted That Met QC Criteria
March 23, 2023
First Posted (Actual)
April 4, 2023
Study Record Updates
Last Update Posted (Actual)
April 4, 2023
Last Update Submitted That Met QC Criteria
March 23, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 70926
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
National Cancer Institute (NCI)Canadian Cancer Trials GroupActive, not recruitingUnresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell CarcinomaUnited States, Canada
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
Clinical Trials on Sodium Pentaborate
-
SB Istanbul Education and Research HospitalBezmialem Vakif UniversityRecruiting
-
Tabriz University of Medical SciencesNot yet recruitingOverweight and ObesityIran, Islamic Republic of
-
University of DelawareCompletedBlood Pressure | Cerebrovascular ReactivityUnited States
-
Institut d'Anesthesiologie des Alpes MaritimesUniversité de Nice Sophia Antipolis; Medical University of GrenobleCompleted
-
Radboud University Medical CenterUnknownType1diabetes | Hypoglycemia UnawarenessNetherlands
-
Austin HealthCompletedSystemic Inflammatory Response Syndrome | Renal Impairment | OliguriaAustralia
-
Medical University of GrazCompleted
-
Brigham and Women's HospitalCompleted
-
Osaka General Medical CenterCompletedEmergent Coronary ProcedureJapan